department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Korsuva · pharmadog

pharmadog
drugs
Korsuva

drug

patient view →

difelikefalin

Marketedupdated 2mo ago

by Vifor Pharma Inc

Approved

community read0 votes

all catalysts(1)

phase 2 initiation · 1

phase 2 initiation

Chittagong Medical College — difelikefalin (Phase II Trial Initiation)

News(0)

no news has mentioned this drug yet

brand

Korsuva

generic

difelikefalin

indication

Uremic (Renal) Pruritus

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 23, 2026

47 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Nov 12, 2027compositionUS 100175361.4y
Nov 12, 2027method-of-use (U-3204)US 101382701.4y
Nov 12, 2027compositionUS 107935961.4y
Nov 12, 2027compositionUS 74025641.4y
Nov 12, 2027compositionUS 77139371.4y
Nov 12, 2027compositionUS 77279631.4y
Nov 12, 2027method-of-use (U-3204)US 82170071.4y
Nov 12, 2027method-of-use (U-3204)US 82367661.4y
Nov 12, 2027method-of-use (U-3204)US 84868941.4y
Nov 12, 2027compositionUS 85361311.4y
Nov 12, 2027method-of-use (U-3204)US 93343051.4y
Nov 12, 2027method-of-use (U-3204)US 93593991.4y

FDA exclusivities (1)

Aug 23, 2026NCENew Chemical Entity (5y)47d

Data sources

ClinicalTrials.gov

last refreshed 56m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagNephrology2 co-mentions · 1 sources
companyChittagong Medical College1 co-mentions · 1 sources
tagDermatology1 co-mentions · 1 sources

Trials studying difelikefalin

phase2Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritusrecruitingn=18
phase3Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Prurituscompletedn=260
phase1Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysiscompletedn=30
phase3Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Parestheticaterminatedn=214
phase3CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritusterminatedn=105
phase3A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritusterminatedn=286
phase3Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitisterminatedn=287
phase2Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)completedn=126

more trials →